Higher antidepressant dose may raise risks for seniors with weak kidneys

NCT ID NCT07387120

First seen Feb 04, 2026 · Last updated Jun 23, 2026 · Updated 19 times

Summary

This completed study looked at nearly 7,000 older adults (65+) with low kidney function who started taking the antidepressant sertraline. Researchers compared the safety of a 50 mg daily dose versus a 25 mg daily dose, tracking hospital visits, emergency department visits, or death within 30 days. The goal was to see if the higher dose poses greater risks in this vulnerable group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • London Health Sciences Centre Research Institute

    London, Ontario, Canada

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Sertraline

What this could lead to

If successful, this could help doctors choose safer antidepressant doses for older adults with kidney problems.

What could go wrong

This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.